

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: February 14, 2005

Signature:

(Jeanne M. Brashear)

Docket No.: 28967/39140B
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Kari Alitalo et al.

Application No.: 10/772,927

Confirmation No.: 7264

Filed: February 4, 2004

Art Unit: 1653

For: VEGF-B AND PDGF MODULATION OF
STEM CELLS

Examiner: Not Yet Assigned

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the Applicants request that the Patent and Trademark Office consider the documents listed on the attached PTO/SB/08 during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom. Copies of documents B15-B17 and C29-C32 are enclosed herewith.

In accordance with 37 CFR 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Supplemental Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention.

This Supplemental Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)). Accordingly, no fees are believed to be due. However, the Director is

Application No.: 10/772,927

Docket No.: 28967/39140B


hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855, under Order No. 28967/39140B. A duplicate copy of this paper is enclosed.

Dated: February 14, 2005

Respectfully submitted,

By Jeanne M. Brashear
Jeanne M. Brashear

Registration No.: 56,301
MARSHALL, GERSTEIN & BORUN LLP
233 S. Wacker Drive, Suite 6300
Sears Tower
Chicago, Illinois 60606-6357
(312) 474-6300
Agent for Applicant



PTO SB 032b (03-03)

Approved for use through 07/31/2005 OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A.B PTO

**SUPPLEMENTAL INFORMATION
DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/772,927-Conf. #7264
Filing Date	February 4, 2004
First Named Inventor	Kari Alitalo
Art Unit	1653
Examiner Name	Not Yet Assigned
Attorney Docket Number	28967/39140B

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A82	US-2002/0022270 A1	02-21-2005	Emerson et al.	
	A83	US-5,753,506	05-19-1998	Johe	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	B15	WO 98/07832	02-26-1998	Ludwig Institute for Cancer Research et al.		
	B16	WO 02/095038	11-28-2002	Fornix Biosciences N.V.		
	B17	WO 03/000009	01-03-2003	Ludwig Institute for Cancer research et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C29	International Search Report, International Application No. PCT/US2004/003316 dated November 23, 2004.	
	C30	Written Opinion, International Application No. PCT/US2004/003316 dated November 23, 2004.	
	C31	Hamada, et al., VEGF-C Signaling Pathways through VEGFR-2 and VEGFR-3 in Vasculoangiogenesis and Hematopoiesis, <i>Blood</i> , 96:3793-3800 (2000).	
	C32	Huang et al., <i>In vitro</i> Effects of Angiopoietins and VEGF on Hematopoietic and Endothelial Cells, <i>Biochem. Biophys. Res. Comm.</i> , 264:133-138 (1999).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
--------------------	-----------------